Drug intelligence / Profile preview

Butoxamine

Development stage: Unknown
Modality: Small Molecules
Administration: Subcutaneous, Oral

Overview

Butoxamine is a selective β2-adrenoceptor antagonist, also known as a beta-2 selective beta blocker. It functions by blocking certain β2-adrenoceptor-mediated responses, particularly in vascular and uterine smooth muscle. Primarily, butoxamine is utilized as a pharmacological tool in experimental settings to characterize β2-adrenoceptors and has no established clinical therapeutic applications. It has also been classified as a hypolipidemic agent, hypoglycemic agent, and sympatholytic.

Other names: butoxamideButaxamineButoxamine HydrochlorideHydrochloride, Butoxamine

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on Butoxamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Butoxamine.

Explore the full profile